State of the art: using natriuretic peptide levels in clinical practice.
about
Focus on renal congestion in heart failurePost-acute care: the role of natriuretic peptidesCardiac biomarkers: new tools for heart failure managementEarly management of patients with acute heart failure: state of the art and future directions. A consensus document from the society for academic emergency medicine/heart failure society of America acute heart failure working groupMorbid obesity: obscuring the diagnosis of aortic stenosis in a patient with cardiogenic wheezingHeart failure in sub-Saharan Africa: review of the aetiology of heart failure and the role of point-of-care biomarker diagnosticsObesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failureChallenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugsErythrocyte transketolase activity, markers of cardiac dysfunction and the diagnosis of infantile beriberiChanges of plasma B-type natriuretic peptide levels after high-pressure post-dilation following coronary stent deploymentAcute Heart Failure Registry: Risk Assessment Model in Decompensated Heart FailureEmerging Affinity-Based Proteomic Technologies for Large-Scale Plasma Profiling in Cardiovascular Disease.Pathophysiology of Heart Failure.The Relation Between Global Longitudinal Strain and Serum Natriuretic Peptide Is More Strict Than That Found Between the Latter and Left Ventricular Ejection Fraction: A Retrospective Study in Chronic Heart Failure.Consequences of high-sensitivity troponin T testing applied in a primary care population with chest pain compared with a commercially available point-of-care troponin T analysis: an observational prospective study.Prognostic significance of biomarkers in predicting outcome in patients with coronary artery disease and left ventricular dysfunction: results of the biomarker substudy of the Surgical Treatment for Ischemic Heart Failure trialsSoluble ST2 as a Diagnostic and Prognostic Marker for Acute Heart Failure Syndromes.Relationship between natriuretic peptides and echocardiography parameters in patients with poorly regulated type 2 diabetesEffect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes.Early postoperative mortality in the elderly: a pilot study.The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial.Effectiveness of a multidisciplinary heart failure disease management programme on 1-year mortality: Prospective cohort studyConcurrent evolution of cancer cachexia and heart failure: bilateral effects exist.Additive value of blood neutrophil gelatinase-associated lipocalin to clinical judgement in acute kidney injury diagnosis and mortality prediction in patients hospitalized from the emergency department.Usefulness of combining galectin-3 and BIVA assessments in predicting short- and long-term events in patients admitted for acute heart failure.Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery.Systemic sclerosis and the heart: current diagnosis and management.In-hospital percentage BNP reduction is highly predictive for adverse events in patients admitted for acute heart failure: the Italian RED Study.B-type natriuretic peptide-guided therapy for perioperative medicine?The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction.Heart failure and chronic obstructive pulmonary disease: Two for tea or tea for two?Two problems with analyzing natriuretic Peptide levels: obesity and acute myocardial infarctionPrognostic significance of a multimarker strategy of biomarkers in acute heart failure.Utility of biomarkers in the differential diagnosis of heart failure in older people: findings from the heart failure in care homes (HFinCH) diagnostic accuracy studyMR-proANP improves prediction of mortality and cardiovascular events in patients with STEMI.Early diagnosis of rats with acute myocardial infarction by measurement of brain natriuretic peptide.Brain natriuretic peptide is not predictive of dilated cardiomyopathy in Becker and Duchenne muscular dystrophy patients and carriers.Improving prognosis estimation in patients with heart failure and the cardiorenal syndromeEarly management of patients with acute heart failure: state of the art and future directions--a consensus document from the SAEM/HFSA acute heart failure working group.Elevated Levels of N-Terminal Pro-Brain Natriuretic Peptide in Patients with Chronic Dyspnea and Moderate Renal Dysfunction: Decreased Clearance or Increased Cardiac Stress?
P2860
Q26769905-054A9B6F-7205-4889-8374-3E6B9FDEB996Q26852607-97EA2EE1-9573-4A54-BF7B-227D84F672E8Q26991726-5AC2153D-CA04-409A-9B74-89A666D03D51Q27000455-E973682E-0938-4BB8-BD03-C6938D1CFE98Q27005608-B9DE9A66-1506-4DD8-8484-7AE94C61C15AQ27015261-113253FC-06E3-4D76-9DD1-F4B4F39B9240Q27027081-84299546-B185-495F-AA6D-44BCD5D29501Q28085736-13A7C0E9-6A50-4B90-83D1-AC7B87D2441DQ28477219-7A5C8728-1833-4F17-90AB-D84B4C9F447AQ28536414-2C2D26DB-EA3C-450A-955E-CF4948AB6C04Q30100975-17BAE7EA-A034-419F-BB70-4CC99B5E9EE3Q30234679-D7AB2FC4-1D1B-4FC4-BB0D-C78B2C17620BQ30315815-C59A6BF5-DA08-44C6-B2C9-7DB7A5361892Q30398937-3599A796-9E32-40C5-AB1F-D1DE8B4F9E13Q30409147-80DCAD3C-C202-43CC-9735-48611FB383E2Q30413291-BD3ECF8F-D543-46AC-8655-31C2349469DCQ30458086-5A740FC3-4CE6-4FAE-8666-E5F867820085Q30481117-2775DDCF-1305-4038-9104-0CDE9C460FB6Q30490289-20F38F2C-A5A8-49DB-9E9F-6B4591A0D0BDQ33477102-7B397D81-2248-4A6A-8CD1-3736FBC91AF2Q33526184-13FAEE33-C8BB-4F2D-84D5-0CB7192C97BCQ33595106-7A13F96F-C82D-4D51-B977-8BEC82F7E519Q33741091-B9274E96-4247-49E7-A14D-CDCF9F42CB0CQ33749925-A9686C78-F29D-4A84-B0B0-65BF7D45968CQ33912126-BADB4ABA-1629-498E-B65F-1A44C287FC83Q33918932-E93B967C-A5E9-4D96-8458-BE78A6590B8CQ34012584-98CFE538-1A82-4319-9758-0EF01D0A8734Q34027034-57C5077D-F04E-4821-A6C6-A813ADB4F79DQ34304406-8442D275-2DCD-4823-AE36-275CFEF4F433Q34343385-B9B10294-1DDA-492C-9BFB-A668618241B0Q34390635-C36FE309-2C73-43F7-A191-AEE02361B618Q34434678-95E8917F-012A-4899-B6B6-B7E3B9CF5973Q34479808-27A1A329-8FBE-435C-9B56-DEA4E5D24F24Q34551529-12FD5BF3-3EA2-4945-9157-C0C9213CAAF2Q34662255-D09D744F-F4B9-499B-A0A2-B73916D194F4Q34676067-259E8E53-F476-473E-AE80-E2F93C0BFFAFQ34840485-16A309AF-D5F4-41D3-8F76-1B572290CEFAQ35020305-0E59F21E-87FA-48BA-A183-4AEAB3849BA1Q35057622-49330C01-4F5A-4ADF-824B-26183765CB47Q35123616-D0D460DC-4922-4E06-8ABE-5271B8D80EB6
P2860
State of the art: using natriuretic peptide levels in clinical practice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
State of the art: using natriuretic peptide levels in clinical practice.
@en
State of the art: using natriuretic peptide levels in clinical practice.
@nl
type
label
State of the art: using natriuretic peptide levels in clinical practice.
@en
State of the art: using natriuretic peptide levels in clinical practice.
@nl
prefLabel
State of the art: using natriuretic peptide levels in clinical practice.
@en
State of the art: using natriuretic peptide levels in clinical practice.
@nl
P2093
P50
P1476
State of the art: using natriuretic peptide levels in clinical practice.
@en
P2093
Alan Maisel
Anthony DeMaria
Christian Mueller
Gerasimos S Filippatos
John G F Cleland
Kenneth McDonald
Kirkwood Adams
Marc Vanderhyden
Marco Tubaro
Markku S Nieminen
P304
P356
10.1016/J.EJHEART.2008.07.014
P50
P577
2008-08-29T00:00:00Z